MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells

Published:2015 Issue:6 Volume:7 Page:643-654
ISSN:1757-9694
Container-title:Integrative Biology
language:en
Short-container-title:Integr. Biol.

Author:

Pak Chorom¹²³⁴²,Callander Natalie S.⁵²³⁶²,Young Edmond W. K.⁷²³,Titz Benjamin⁸⁹²³¹⁰,Kim KyungMann⁶²³¹¹⁹,Saha Sandeep¹¹⁹²³,Chng Kenny⁴²³,Asimakopoulos Fotis⁵²³⁶²,Beebe David J.⁶²³⁷²,Miyamoto Shigeki¹²³⁴²

Affiliation:

1. Molecular and Cellular Pharmacology Graduate Program

2. Madison

3. USA

4. Department of Oncology

5. Department of Medicine, Section of Hematology/Oncology

6. University of Wisconsin Carbone Cancer Center

7. Department of Biomedical Engineering

8. Department of Medical Physics

9. University of Wisconsin-Madison

10. Cellectar Biosciences, Inc.

11. Department of Biostatistics and Medical Informatics

Abstract

We have developed a microfluidicscis-coculture assay platform to identify myeloma patient responsesex vivo.

Funder

National Institutes of Health

Multiple Myeloma Research Foundation

Publisher

Oxford University Press (OUP)

Subject

Biochemistry,Biophysics

Link

http://pubs.rsc.org/en/content/articlepdf/2015/IB/C5IB00071H

Reference76 articles.

1. In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group

2. Chemotherapy Sensitivity and Resistance Assays: A Systematic Review

3. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

4. Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer

5. Multiple Myeloma

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on Phenotypic Screening−Screen Design and Assay Technology Special Interest Group;SLAS Discovery;2024-02

2. PTOLEMI: Personalized Cancer Treatment through Machine Learning-Enabled Image Analysis of Microfluidic Assays;Diagnostics;2023-09-28

3. In vitro models of breast cancer bone metastasis: analyzing drug resistance through the lens of the microenvironment;Frontiers in Oncology;2023-04-11

4. Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies;Pharmaceuticals;2023-01-12

5. Current insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo;Biomaterials;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3